DocG DocG | AI-Powered Clinical Summaries
Sign In

Stay Current with Medical Literature

AI-powered clinical summaries delivered to your inbox 3 times per week. Evidence-based insights in 300 words, designed for busy physicians.

Sign Up

See What You Get

Subscribers receive email summaries and access to our interactive AI-powered article rankings.

Email Summary Example

Benefit greatest in higher-risk COVID-19 outpatients
Among outpatients in the Omicron period, nirmatrelvir plus ritonavir was linked to fewer hospitalizations and deaths, with the largest absolute benefit in moderate- and high-risk patients.
*Systematic review and meta-analysis of cohort studies; Level 2a (OCEBM).

Citation

Ebell M, Kurotschka P. Effectiveness of Nirmatrelvir/Ritonavir for Outpatients in the Era of Omicron, Vaccination, and Previous Infection: A Meta-analysis. Journal of General Internal Medicine. 2026. doi:10.1007/s11606-026-10494-4

Background

Earlier trials of nirmatrelvir plus ritonavir (Paxlovid) occurred before widespread vaccination and prior infection. This review asked whether it still helps prevent hospitalization and death among contemporary outpatients.

Patients

Adults and adolescents (12 years or older) with COVID-19 managed as outpatients during the Omicron period (data collection started no earlier than December 2021). Excluded: initially hospitalized patients; studies without adjusted analyses; non–peer-reviewed reports; and special populations (such as pregnancy or specific diseases like cancer or transplant).

Intervention

Nirmatrelvir plus ritonavir.

Control

No antiviral treatment.

Outcome

30-day hospitalization (all-cause and COVID-19-related) and 30-day death (all-cause and COVID-19-related); also a combined outcome of hospitalization or death.

Follow-up Period

30 days.

Results

Outcome (30-day) Pooled adjusted relative risk (95% confidence interval)
All-cause hospitalization 0.54 (0.43 to 0.68)
COVID-19 hospitalization (primary) 0.45 (0.36 to 0.56)
All-cause death 0.30 (0.23 to 0.39)
Estimated number needed to treat to prevent one COVID-19 hospitalization (using external baseline-risk groups): low risk 1148; moderate risk 84; high risk 20.

Limitations

All included studies were observational, so unmeasured differences between treated and untreated groups may still explain part of the benefit. Results varied across studies, and definitions of “immunocompromised” and outcomes differed. For low-risk patients, the absolute benefit is very small despite favorable relative risk.

Funding

No project-specific funding reported.

Clinical Application

Use nirmatrelvir plus ritonavir mainly for moderate- and high-risk outpatients; expect minimal absolute benefit in low-risk patients and prioritize shared decision-making and drug–drug interaction review.

Top Journal Rankings - August 2026

66 abstracts scored across 7 criteria. Click any article to expand criterion scores.
1. 8.0
Effectiveness of Nirmatrelvir/Ritonavir for Outpatients in the Era of Omicron, Vaccination, and Previous Infection: A Meta-analysis.
Overall: This large contemporary meta-analysis supports meaningful reductions in hospitalization and death with nirmatrelvir-ritonavir among higher-risk outpatients, although reliance on observational studies and absent harm data limit certainty.
View 6 Criterion Scores
Primary-Care Relevance & Applicability 9.0
COVID-19 treatment is a common outpatient decision, and the risk-stratified findings directly inform prescribing in US primary care.
Validity, Bias Control & Precision 7.5
The meta-analysis included 47 adjusted cohort studies and more than 10 million patients, assessed study quality, and reported confidence and prediction intervals, but nonrandomized evidence remains vulnerable to residual confounding.
Patient-Oriented Outcomes 10.0
Hospitalization and mortality are clearly patient-important outcomes.
Magnitude of Net Benefit 7.0
Relative reductions were substantial, but absolute benefit varied markedly: the hospitalization NNT was 20 in high-risk patients, 84 in moderate-risk patients, and 1148 in low-risk patients; harms and treatment burden were not reported.
Implementability & Practicality 7.0
The intervention is an outpatient drug treatment and the risk-stratified results are actionable, although the abstract provides no information about treatment harms, access, or workflow barriers.
Practice-Changing Potential 7.5
The findings support targeted treatment of moderate- and high-risk outpatients while showing minimal absolute benefit for low-risk patients, potentially refining routine prescribing.
2. 7.9
Calcium, vitamin D, or combined supplementation to prevent fractures and falls: systematic review and meta-analysis.
Overall: This rigorous, highly applicable meta-analysis shows that routine calcium or vitamin D supplementation offers little to no fracture or fall prevention benefit for most community-dwelling adults.
View 6 Criterion Scores
Primary-Care Relevance & Applicability 10.0
Fracture prevention and routine calcium or vitamin D supplementation are common decisions in US primary care, and most participants were community-dwelling adults.
Validity, Bias Control & Precision 9.5
This systematic review included 69 randomized trials and 153,902 participants, used independent review, Cochrane risk-of-bias assessment, random-effects analyses, GRADE, and extensive subgroup analyses.
Patient-Oriented Outcomes 9.5
The review directly measured fractures, hip fractures, vertebral and nonvertebral fractures, falls, and total falls, all of which are important to patients.
Magnitude of Net Benefit 1.0
Calcium, vitamin D, and combined supplementation produced little to no clinically meaningful reduction in fractures or falls; harms were not reported in the abstract.
Implementability & Practicality 9.0
The findings can be readily applied to routine supplement counseling without specialized equipment, training, or monitoring.
Practice-Changing Potential 8.5
The large, high-certainty evidence base could discourage routine supplementation solely to prevent fractures or falls in generally low-risk, community-dwelling adults.
3. 7.7
Kidney and Survival Benefits of Semaglutide in Diabetes With Chronic Kidney Disease: FLOW Trial Cardiovascular Subgroup Analyses.
Overall: A large randomized trial supports meaningful kidney and possible survival benefits from semaglutide in a highly relevant primary-care population, though the subgroup design and absent safety information limit certainty about net benefit.
View 6 Criterion Scores
Primary-Care Relevance & Applicability 9.0
Type 2 diabetes with CKD is commonly managed in US primary care, and semaglutide prescribing is directly relevant to outpatient treatment decisions.
Validity, Bias Control & Precision 8.0
This large randomized placebo-controlled trial included more than 3,500 participants and reported event counts, confidence intervals, and interaction tests, although these are subgroup analyses.
Patient-Oriented Outcomes 8.5
The study assessed major CKD progression and all-cause mortality, although the primary kidney composite also incorporated eGFR-based components.
Magnitude of Net Benefit 6.5
Kidney benefits were clinically meaningful, with three-year numbers needed to treat of 13 to 22 in major cardiovascular subgroups, but several subgroup confidence intervals crossed 1 and harms were not reported.
Implementability & Practicality 7.0
Once-weekly semaglutide is familiar and feasible in outpatient practice, but it requires injections and the abstract does not address treatment burden, adverse effects, or access.
Practice-Changing Potential 7.0
The findings support semaglutide across cardiovascular-risk strata in diabetes with CKD, but subgroup analyses mainly extend and reinforce the parent trial rather than independently establish a new practice.
4. 7.3
Maternal Respiratory Syncytial Virus Prefusion F Vaccination and Acute Respiratory Illness in Infants.
Overall: This clinically relevant US study reports a large reduction in infant RSV hospitalization after maternal vaccination, but its modest sample, observational design, wide confidence intervals, and lack of absolute benefit or safety data limit certainty.
View 6 Criterion Scores
Primary-Care Relevance & Applicability 8.0
This US study addresses maternal vaccination to prevent severe RSV illness in young infants, a common preventive-care decision relevant to prenatal and family medicine practice.
Validity, Bias Control & Precision 6.0
The test-negative design and adjusted analysis strengthen the findings, but this was a retrospective, single-health-system study with only 274 infants and wide confidence intervals.
Patient-Oriented Outcomes 9.0
The outcomes—hospitalization for RSV-associated acute respiratory illness and lower respiratory tract disease—are directly important to infants and families.
Magnitude of Net Benefit 7.0
Estimated effectiveness against hospitalization was substantial at approximately 68% to 69%, although absolute risk reduction, adverse effects, and vaccination burden were not reported.
Implementability & Practicality 8.0
The vaccine is licensed in the US and can be incorporated into prenatal care, though administration is restricted to a defined gestational window and timing before delivery.
Practice-Changing Potential 6.0
The study provides useful early postlicensure evidence supporting maternal RSV vaccination, but its observational design, limited sample, and single-system setting make it more confirmatory than independently practice-changing.
5. 7.3
Adverse Effects and Treatment Discontinuation of Blood Pressure-Lowering Drugs and Combinations: A Network Meta-Analysis.
Overall: This large and rigorous analysis directly informs common hypertension prescribing, but its modest absolute differences and short-term tolerability focus make it more useful for refining treatment choices than transforming practice.
View 6 Criterion Scores
Primary-Care Relevance & Applicability 10.0
Hypertension treatment and selection among these five widely used drug classes are routine decisions in US outpatient primary care.
Validity, Bias Control & Precision 9.0
The network meta-analysis included 716 double-blind randomized trials and 159,362 participants, used independent data extraction, and reported credible intervals and absolute differences; limitations include short follow-up, trial-level data, and network assumptions.
Patient-Oriented Outcomes 6.5
Treatment discontinuation due to adverse effects and symptoms such as dizziness, edema, cough, and headache matter to patients, but long-term cardiovascular outcomes, function, and quality of life were not assessed.
Magnitude of Net Benefit 3.5
Differences in discontinuation were statistically significant but small in absolute terms, generally about 0.8% to 1.7%, and all regimens increased dizziness.
Implementability & Practicality 9.0
The evaluated medications are familiar and widely available, so the tolerability findings can be incorporated into prescribing without specialized equipment or major workflow changes.
Practice-Changing Potential 6.0
The findings may refine initial drug or combination selection, especially favoring ARB-containing regimens for tolerability, but small effects and follow-up averaging only 8.6 weeks limit major practice change.
6. 7.3
Impact of treatment duration on the effectiveness of opioid analgesia: a systematic review and meta-analysis.
Overall: A directly relevant systematic review suggests that opioid analgesia may lose benefit with longer treatment, but missing quantitative results and safety details limit confidence in the size of the clinical effect.
View 6 Criterion Scores
Primary-Care Relevance & Applicability 9.0
Chronic low back pain, osteoarthritis, and decisions about opioid duration are common and directly relevant to US primary care.
Validity, Bias Control & Precision 6.5
This systematic review included 27 randomized trials, multiple databases, and random-effects meta-analysis, but the abstract omits sample sizes, numerical estimates, confidence intervals, and risk-of-bias findings.
Patient-Oriented Outcomes 8.0
The primary outcome was clinically important pain relief of at least 30%, a meaningful outcome for patients, with on-treatment pain assessed secondarily.
Magnitude of Net Benefit 5.0
Opioids reportedly provided meaningful short-term relief but little or no longer-term benefit and possibly worse pain after 12 weeks; absent numerical effects prevent firm assessment of magnitude.
Implementability & Practicality 8.5
Limiting prolonged opioid therapy is readily actionable in outpatient care, although changing treatment may require tapering, follow-up, and alternative pain-management strategies.
Practice-Changing Potential 7.0
The duration-dependent findings could reinforce shorter opioid courses and discourage long-term treatment, but incomplete effect estimates limit stand-alone practice-changing certainty.
7. 7.3
All-cause and cause-specific mortality assessment in patients receiving sodium glucose co-transporter-2 inhibitors.
Overall: A large randomized-trial meta-analysis supports cardiovascular mortality benefit from a highly relevant therapy, but neutral all-cause mortality, absent absolute effects and safety data, and exploratory subgroup findings limit its practice-changing impact.
View 6 Criterion Scores
Primary-Care Relevance & Applicability 9.0
SGLT2 inhibitors are commonly prescribed in US primary care for diabetes, heart failure, and chronic kidney disease.
Validity, Bias Control & Precision 8.5
This random-effects meta-analysis included 18 randomized trials and 95,913 patients, although risk-of-bias findings, heterogeneity, and absolute event rates were not reported.
Patient-Oriented Outcomes 10.0
The study evaluated all-cause and cause-specific mortality, which are definitive patient-important outcomes.
Magnitude of Net Benefit 5.5
Cardiovascular mortality was reduced, but all-cause mortality was not significantly improved, renal mortality was imprecise, and absolute benefits and adverse effects were not reported.
Implementability & Practicality 8.0
SGLT2 inhibitors are established therapies that can be prescribed in routine outpatient care, though the abstract provides no information about cost, monitoring, or treatment burden.
Practice-Changing Potential 3.0
The findings reinforce an existing cornerstone therapy rather than establish a substantially new practice, while the age-subgroup results are explicitly exploratory.
8. 7.1
Deprescribing Intervention and Reduction of Proton Pump Inhibitor Use in Primary Care: A Cluster Randomized Clinical Trial.
Overall: This large, precise primary-care trial demonstrates that a simple patient-and-clinician intervention meaningfully reduces long-term PPI use without detected worsening of reflux symptoms, although its main outcome is medication utilization rather than direct patient benefit.
View 6 Criterion Scores
Primary-Care Relevance & Applicability 8.5
Long-term PPI prescribing and deprescribing are common primary-care decisions, and the intervention is readily transferable despite being studied in France.
Validity, Bias Control & Precision 8.5
This was a large pragmatic cluster-randomized trial involving 34,409 patients, with an appropriate usual-care comparator and precise absolute estimates; open-label delivery and claims-based outcome measurement are limitations.
Patient-Oriented Outcomes 3.5
The primary outcome was reduced medication use rather than a direct health outcome, while reflux impact was assessed only in a 10% sample and showed no significant difference.
Magnitude of Net Benefit 7.0
The combined intervention increased substantial PPI dose reduction by 6.9 percentage points without a meaningful detected worsening in reflux activity, although adverse events were not reported.
Implementability & Practicality 9.0
Mailing a patient brochure and providing clinicians with a deprescribing algorithm are inexpensive, scalable measures requiring little training or monitoring.
Practice-Changing Potential 6.0
The trial supports adding direct patient education to clinician-only deprescribing guidance, but it does not establish improvement in clinical outcomes or complete medication discontinuation.
9. 7.1
Preventing Postvaccination Presyncope and Syncope in Adolescents: A Randomized Controlled Trial of a Clinic-Based Intervention.
Overall: A relevant randomized trial found a sizable reduction in postvaccination presyncope using a feasible clinic intervention, but reliance on a surrogate outcome and incomplete safety and precision reporting limit its practice-changing strength.
View 6 Criterion Scores
Primary-Care Relevance & Applicability 9.0
Routine adolescent vaccination and prevention of postvaccination symptoms are directly relevant to US primary care.
Validity, Bias Control & Precision 7.5
This was a registered randomized controlled trial with 332 participants and modified intention-to-treat analysis, but blinding, confidence intervals, and detailed attrition information were not reported.
Patient-Oriented Outcomes 5.5
Presyncope and pain matter to patients, but presyncope was explicitly used as a surrogate for the more consequential outcome of syncope.
Magnitude of Net Benefit 7.0
Presyncope decreased by 12 percentage points, a clinically meaningful absolute difference, although harms were not described and the reported pain-score direction appears inconsistent with the stated conclusion.
Implementability & Practicality 7.5
A vibration/cooling device and tablet-based distraction could be incorporated into vaccination workflows, though they require equipment, setup, and staff coordination.
Practice-Changing Potential 6.0
The intervention could improve adolescent vaccination visits, but a single moderate-sized trial centered on a surrogate outcome is unlikely to establish routine practice by itself.
10. 7.1
Amoxicillin-Clavulanate vs Amoxicillin for Acute Sinusitis in Adults.
Overall: This large outpatient cohort supports readily implementable use of amoxicillin without higher treatment failure and with slightly fewer infections, although residual confounding and the claims-based composite outcome limit certainty.
View 6 Criterion Scores
Primary-Care Relevance & Applicability 9.0
Acute sinusitis and first-line antibiotic selection are common outpatient decisions, although the abstract does not explicitly identify the country represented by the nationwide database.
Validity, Bias Control & Precision 6.5
The very large active-comparator cohort, propensity matching, sensitivity analyses, and narrow confidence intervals strengthen the findings, but the retrospective observational design remains vulnerable to residual confounding and outcome misclassification.
Patient-Oriented Outcomes 5.5
Treatment escalation, emergency or inpatient encounters, and infections are clinically relevant, but the primary composite was dominated by subsequent antibiotic dispensing and did not measure symptom resolution or quality of life.
Magnitude of Net Benefit 4.5
Treatment failure was essentially identical, while amoxicillin-clavulanate produced small absolute increases in yeast infection and very rare Clostridioides difficile infection, favoring amoxicillin modestly.
Implementability & Practicality 10.0
Choosing amoxicillin instead of amoxicillin-clavulanate requires no new equipment, training, monitoring, or workflow and can be implemented immediately.
Practice-Changing Potential 7.0
The findings could shift prescribing toward amoxicillin for uncomplicated sinusitis, but observational evidence alone may not definitively resolve first-line recommendations.
Score Guide: 9-10 Exceptional 7-8 Strong 5-6 Moderate 3-4 Weak 1-2 Poor
Showing top 10 of 66

How It Works

1

Sign Up with Google

Create your account in seconds using your Google account. No passwords to remember.

2

Receive Email Summaries

Get AI-curated clinical summaries delivered to your inbox three times per week (Monday, Wednesday, Friday).

3

Find the Best New Articles

Our interactive article rankings allow you to find the best articles, tailored to you.

Ready to Stay Current?

Sign Up